BofA warns Fed risks policy mistake with early rate cuts
BOSTON/LONDON - PureTech Health plc (Nasdaq:PRTC, LSE: PRTC) will announce its half-yearly financial results for the six months ended June 30, 2025, on Thursday, August 28, 2025, according to a company press release.
The clinical-stage biotherapeutics company has scheduled a presentation and conference call for analysts and shareholders at 9:00 AM EDT / 2:00 PM BST on the day of the results publication. A webcast of the presentation will be available on the company’s investor relations website.
PureTech focuses on developing new classes of medicine for patients with serious diseases. The company has built a portfolio of 29 therapeutics and therapeutic candidates through its research and development team and network of scientists, clinicians, and industry leaders.
Three of PureTech’s therapeutics have received approval from the U.S. Food and Drug Administration. The company reports that several programs are advancing through various clinical development stages, including registration-enabling studies, either directly by PureTech or through its Founded Entities.
The company identifies, discovers, and advances underlying programs and platforms through its research engine, taking them through key validation points before development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.